HERON THERAPEUTICS, INC. /DE/ Earnings Per Share (Basic)
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Earnings Per Share (Basic) of -$0.03 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-10
- HERON THERAPEUTICS, INC. /DE/ earnings per share, basic for the quarter ending 2026-06-30 was -$0.03.
- HERON THERAPEUTICS, INC. /DE/ earnings per share, basic for the quarter ending 2026-03-31 was -$0.04, a 300.00% decline year-over-year.
- HERON THERAPEUTICS, INC. /DE/ earnings per share, basic for the quarter ending 2025-12-31 was -$0.01, a 169.21% decline year-over-year.
- HERON THERAPEUTICS, INC. /DE/ earnings per share, basic for the quarter ending 2025-09-30 was -$0.10.
- HERON THERAPEUTICS, INC. /DE/ earnings per share, basic for fiscal 2025 was -$0.12.
- HERON THERAPEUTICS, INC. /DE/ earnings per share, basic for fiscal 2024 was -$0.09.
- HERON THERAPEUTICS, INC. /DE/ earnings per share, basic for fiscal 2023 was -$0.80.
- HERON THERAPEUTICS, INC. /DE/ earnings per share, basic for fiscal 2022 was -$1.67.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.03 10-Q · filed 2026-08-10 | -$0.07 10-Q · filed 2026-08-10 | -$0.09 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2026-03-31 | -$0.04 10-Q · filed 2026-05-11 | -$0.06 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$0.16 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2025-12-31 | -$0.01 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.11 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.13 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$0.12 10-K · filed 2026-02-26 |
| 2025-09-30 | -$0.10 10-Q · filed 2025-11-04 | -$0.12 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$0.11 10-Q · filed 2025-11-04 | -$0.09 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2025-06-30 | -$0.02 10-Q · filed 2026-08-10 | $0.00 10-Q · filed 2026-08-10 | $0.02 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$0.01 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2025-03-31 | $0.02 10-Q · filed 2026-05-11 | $0.04 derived: net income ÷ weighted average shares · filed 2026-08-10 | $0.01 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$0.05 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2024-12-31 | $0.02 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.01 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.07 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.09 10-K · filed 2026-02-26 |
| 2024-09-30 | -$0.03 10-Q · filed 2025-11-04 | -$0.09 derived: net income ÷ weighted average shares · filed 2025-11-04 | -$0.11 10-Q · filed 2025-11-04 | -$0.19 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2024-06-30 | -$0.06 10-Q · filed 2025-08-08 | -$0.08 10-Q · filed 2025-08-08 | -$0.16 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.32 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2024-03-31 | -$0.02 10-Q · filed 2025-05-06 | -$0.09 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2023-12-31 | -$0.07 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.24 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.80 10-K · filed 2026-02-26 |
| 2023-09-30 | -$0.17 10-Q · filed 2024-11-12 | -$0.51 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$0.75 10-Q · filed 2024-11-12 | -$0.95 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2023-06-30 | -$0.35 10-Q · filed 2024-08-06 | -$0.63 10-Q · filed 2024-08-06 | -$0.79 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.16 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2023-03-31 | -$0.27 10-Q · filed 2024-05-07 | -$0.44 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.81 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.33 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2022-12-31 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.53 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.06 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.67 10-K · filed 2025-02-27 |
| 2022-09-30 | -$0.38 10-Q · filed 2023-11-14 | -$0.92 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$1.54 10-Q · filed 2023-11-14 | -$35.04 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2022-06-30 | -$0.55 10-Q · filed 2023-08-14 | -$1.18 10-Q · filed 2023-08-14 | $6.05 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$60.87 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2022-03-31 | -$0.63 10-Q · filed 2023-05-11 | $1.26 derived: net income ÷ weighted average shares · filed 2026-04-30 | $5.88 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$84.37 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2021-12-31 | $0.19 derived: net income ÷ weighted average shares · filed 2026-04-30 | $1.13 derived: net income ÷ weighted average shares · filed 2026-04-30 | $5.54 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$2.24 10-K · filed 2023-03-29 |
| 2021-09-30 | -$0.51 10-Q · filed 2022-11-08 | -$1.13 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$1.71 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$0.62 10-Q · filed 2022-08-09 | -$1.20 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |